COMPASS

The rise in cardiovascular disease among cancer patients and survivors, due to treatment side effects, poses a significant challenge to patient outcomes and healthcare systems. Managing cardiotoxicity is difficult due to its delayed onset and lack of reliable biomarkers, often requiring dose reduction or discontinuation of cancer treatment, which may compromise its effectiveness.

The COMPASS project aims to optimize cardiovascular health for cancer patients and survivors through a comprehensive, patient-centered clinical pathway over five years. It will advance cardio-oncology research by creating an international network and developing tools for better disease prediction, prevention, diagnosis, and management. The project focuses on integrating cardiooncology care pathways, optimizing diagnostic biomarkers, and utilizing AI-supported imaging and wearable technologies for early detection and personalized treatment, while promoting sustainable healthcare delivery and reducing environmental impact.

COMPASS methodology includes three pillars: (i) Discovery of Novel Biomarkers and Parameters, (ii) AI Prediction Models and Clinical Decision Support System, and (iii) Improving Care Delivery and Patient Engagement. Activities across the program include Health Economics, Communication, Dissemination, Exploitation and Sustainability, and Ethics and Regulatory Aspects. 67 academic and industrial partners will collaborate to translate scientific advancements into clinical applications, apply novel AI approaches, ensuring solutions are effective, meet patient needs, and align with European health policies and regulations. Key stakeholders include clinicians, nurses, patients, payers, regulators, and industry actors. COMPASS aims to advance cardio-oncology research, reduce healthcare costs, and improve patient well-being through innovative tools, collaborative networks, and policy support. Ultimately, it aims to improve patient outcomes for both cancer and heart health.

The CERTH/ITI participates in the COMPASS project, taking on a significant role across five work packages (WP2, WP4, WP5, WP6, WP10, WP11), with primary involvement in WP6. More specifically, CERTH/ITI contributes to the exploitation of cancer data for improved risk prediction (T2.3), to the development and validation of cardiovascular toxicity prediction models based on clinical characteristics and echocardiography data (T4.2, T4.4, T4.5, T4.6), as well as to the creation of a digital monitoring platform for continuous data collection from wearable devices and the application of artificial intelligence for real-time assessment (T5.2, T5.3, T5.4). Furthermore, CERTH/ITI is responsible for the development of a digital patient model, visual analytics for clinical decision support, the creation of a patient monitoring dashboard and, most notably, for ensuring the trustworthiness and compliance of artificial intelligence systems with the European AI Act (T6.1, T6.3, T6.4, T6.5, T6.6).

Consortium

(COORD) KCL (King’s College London)
(Co-COORD) FPG (Fondazione Policlinico Universitario Agostino Gemelli IRCCS)
(COORD) GEHC HU (GE Healthcare Magyarország Kft.)
(Affiliated Entity,AE) GEHC ISR (GE Medical Systems Israel LTD)
(AE) GEHC CVUS (GE Vingmed Ultrasound AS)
(AE) GEHC FR (GE Medical Systems SCS)
(AE) GEHC DE (GE Healthcare GMBH)
(AE) GEHC FIN (GE Healthcare Finland OY)
(AE) GEUS LLC (GE Precision Healthcare LLC)
(AE) GEHC AT (GE Healthcare Austria GMBH & CO OG)
(AE) GEUS IITS (GE Healthcare IITS USA Corp)
(AE) GEHC UK (GE Medical Systems Limited)
(AE) GEHC DK (GE Healthcare Danmark A/S)
ASC (Exploraciones Radiológicas Especiales S.L. – Ascires Biomedical Group)
ATRYS (Atrys Health SA)
HICT (Hict NV)
GEN (Genomate Health Hungary Kft.)
MEDT (Medtronic Ibérica SA)
ROCHE (F. Hoffmann-La Roche AG)
ZAB (Zabala Innovation Consulting SA)
ARMA (Arma Biosciences)
BRD (BRIDG OU)
DW (Datawizard S.R.L.)
FWD (Forward Faster AI B.V.)
Aktiia (Aktiia SA)
Acorai (IAROCA AB)
Multiverse (Multiverse Computing SL)
SPR (Spear UG)
SRI (Syreon Kutato Intezet Kft.)
Telicent (Telicent Limited)
LIVV (Themi Consulting BV)
AU (Aarhus Universitet)
BIU (Bar-Ilan University)
HMO (Hadassah Medical Organization)
IJB (Institut Jules Bordet / Hôpital Universitaire de Bruxelles)
KUL (Katholieke Universiteit Leuven)
LUMC (Leids Universitair Medisch Centrum)
NTNU (Norges Teknisk-Naturvitenskapelige Universitet)
IESE (Universidad de Navarra)
UPorto (Universidade do Porto)
UNICAL (Università della Calabria)
UKHD (University Hospital Heidelberg)
RBH (Royal Brompton Hospital)
SERMAS (Servicio Madrileño de Salud)
(AE) FIBHGM (Fundación para la Investigación Biomédica Hospital Gregorio Marañón)
(AE) FIBHULP (Fundación para la Investigación Biomédica del Hospital Universitario La Paz)
UCL (Université catholique de Louvain)
(AE) CUSL (Cliniques Universitaires Saint-Luc asbl)
OUH (Oxford University Hospital)
EPC (Észak Pesti Centrumkórház – Honvédkórház)
FEOR (Fundación Española de Oncología Radioterápica)
GHH (Global Heart Hub Company Limited by Guarantee)
Bioaster (Bioaster Fondation de Cooperation Scientifique)
CNIC (Centro Nacional de Investigaciones Cardiovasculares Carlos III)
CSEM (CSEM – Centre Suisse d’Electronique et de Microtechnique)
CERTH (Ethniko Kentro Erevnas Kai Technologikis Anaptyxis)
Fraunhofer (Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung EV)
VICOM (Fundación Centro de Tecnologías De Interacción Visual y Comunicaciones Vicomtech)
IDIBAPS (Fundació de Recerca Clínic Barcelona – Institut d’Investigacions Biomèdiques August Pi i Sunyer)
(AE) HCB (Hospital Clínic de Barcelona)
IGR (Institut Gustave Roussy)
(AE) GRT (Gustave Roussy Transfert)
HMGU (Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH)
KBFI (Keemilise ja Bioloogilise Füüsika Instituut)
AUMC (Stichting Amsterdam UMC)
TUBITAK (The Scientific and Technological
UNICANCER (Unicancer)